Subscribe
ugisrigba
Ugis Rigba / Shutterstock.com
28 May 2020Big PharmaRory O'Neill

Report slams big pharma influence in EU-funded project

A  new NGO report has sharply criticised the EU-funded Innovative Medicines Initiative (IMI) as favouring Big Pharma over small businesses, particularly when it comes to IP.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Will the EU’s SPC manufacturing waiver weaken European pharma’s IP?
20 May 2020   Despite dire warnings by the US Chamber of Commerce, the impact of the EU’s SPC waiver won’t be known for years, says Paul Williams of Lewis Silkin.
Big Pharma
EMA unveils fast-track drug shortage monitoring
8 April 2020   The EU’s drugs regulator has set up a fast-track system to monitor shortages during the COVID-19 pandemic.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Will the EU’s SPC manufacturing waiver weaken European pharma’s IP?
20 May 2020   Despite dire warnings by the US Chamber of Commerce, the impact of the EU’s SPC waiver won’t be known for years, says Paul Williams of Lewis Silkin.
Big Pharma
EMA unveils fast-track drug shortage monitoring
8 April 2020   The EU’s drugs regulator has set up a fast-track system to monitor shortages during the COVID-19 pandemic.

More on this story

Americas
Will the EU’s SPC manufacturing waiver weaken European pharma’s IP?
20 May 2020   Despite dire warnings by the US Chamber of Commerce, the impact of the EU’s SPC waiver won’t be known for years, says Paul Williams of Lewis Silkin.
Big Pharma
EMA unveils fast-track drug shortage monitoring
8 April 2020   The EU’s drugs regulator has set up a fast-track system to monitor shortages during the COVID-19 pandemic.

More features

President Trump 2.0: Five major areas to watch
China’s new policies on foreign investment in healthcare and biotech
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?